Disclosures: Rajan Vijayaraghavan: Nothing to Disclose, Ankit Bharadwaj: Nothing to Disclose, Vinod Arora: Nothing to Disclose, Gaurav Sidhwani: Nothing to Disclose, Uma Kanal: Nothing to Disclose, Rakhi Maiwall: Nothing to Disclose, Ashok Kumar Choudhury: Nothing to Disclose, Harsh Tevethia: Nothing to Disclose, Jaya Benjamin: Nothing to Disclose, Satender Pal Singh: Nothing to Disclose, CHITRANSHU VASHISHTHA: Nothing to Disclose, Manoj Sharma: Nothing to Disclose, Shiv Kumar Sarin: Nothing to Disclose 2594 IMPACT OF LAPAROSCOPIC SURGERY VERSUS OPEN SURGERY ON LONG-TERM OUTCOMES AND HEALTHCARE UTILIZATION IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND SEVERE OBESITY Xinrong Zhang 1 Nicholas Rouillard 1 Xianhua Mao 2 Rongtao Lai 3 Ramsey Cheung 4 Kazunari Sasaki 5 , 1 Division of Gastroenterology and Hepatology, School of Medicine, Stanford University, 2 Department of Medicine, School of Clinical Medicine, The University of Hong Kong, 3 Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 4 Stanford University Medical Center, 5 Department of Surgery, School of Medicine, Stanford University Background: Bariatric surgery has been recognized as a potential treatment for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity
Grassi G, Mark A, Esler M
IL-6 deficiency attenuates skeletal muscle atrophy by inhibiting mitochondrial ROS production through the upregulation of PGC-1 in septic mice
Acute kidney injury : Though rare, any GLP-1 receptor agonist can potentially cause dehydration (particularly if severe vomiting or diarrhoea occurs), which may precipitate kidney problems
Research indicates that users can expect to lose, on average, 15-20% of their body weight, positioning it among the most effective weight-loss medications available today
